Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EBITDA: 2011-2024

Historic EBITDA for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $139.0 million.

  • Adma Biologics' EBITDA rose 28.69% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $167.0 million, marking a year-over-year increase of 45.36%. This contributed to the annual value of $139.0 million for FY2024, which is 542.49% up from last year.
  • Latest data reveals that Adma Biologics reported EBITDA of $139.0 million as of FY2024, which was up 542.49% from $21.6 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' EBITDA ranged from a high of $139.0 million in FY2024 and a low of -$64.9 million during FY2020.
  • Its 3-year average for EBITDA is $40.4 million, with a median of $21.6 million in 2023.
  • Data for Adma Biologics' EBITDA shows a peak YoY spiked of 542.49% (in 2024) over the last 5 years.
  • Over the past 5 years, Adma Biologics' EBITDA (Yearly) stood at -$64.9 million in 2020, then grew by 10.08% to -$58.4 million in 2021, then surged by 32.56% to -$39.4 million in 2022, then surged by 154.95% to $21.6 million in 2023, then spiked by 542.49% to $139.0 million in 2024.